Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143281 | 1.00 | CA2 (0.62) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL7960313 | 0.95 | TDP1 (0.61) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL5537767 | 0.89 | CA2 (0.75) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL6787910 | 0.89 | CA2 (0.75) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL28789388 | 0.85 | CA2 (0.67) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL13229 | 0.85 | CA2 (0.67) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL13230 | 0.85 | CA2 (0.67) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL4893223 | 0.82 | ALDH1A1 (0.66) | CA2ALDH1A1L3MBTL1 | |
| SCHEMBL2226530 | 0.82 | ALDH1A1 (0.66) | CA2ALDH1A1L3MBTL1 | |
| SCHEMBL13804351 | 0.82 | GAA (0.53) | L3MBTL1TDP1RECQLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-6867211-B2 | 4-Pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy | MERCKLE GMBH (DE) | 2005-03-15 | — | — | US | disclosed |
| EP-1252163-B1 | 4-PYRIDYL-AND 2,4-PYRIMIDINYL-SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE IN PHARMACY | MERCKLE GMBH (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20030153558-A1 | 4-Pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy | MERCKLE GMBH (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1252163-A2 | 4-PYRIDYL-AND 2,4-PYRIMIDINYL-SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE IN PHARMACY | MERCKLE GMBH (DE) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001057042-A2 | 4-PYRIDYL-AND 2,4-PYRIMIDINYL-SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE IN PHARMACY | MERCKLE GMBH (DE) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | CA2 1113/4885ALDH1A1 276/4885L3MBTL1 3221/4885 |
| US-20030153558-A1 | 4-Pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy | IL4, IL2, IL5 | CA2 3163/4885ALDH1A1 524/4885L3MBTL1 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.